2,318 reports of this reaction
2.9% of all LIRAGLUTIDE reports
#5 most reported adverse reaction
PANCREATITIS is the #5 most commonly reported adverse reaction for LIRAGLUTIDE, manufactured by Novo Nordisk. There are 2,318 FDA adverse event reports linking LIRAGLUTIDE to PANCREATITIS. This represents approximately 2.9% of all 79,181 adverse event reports for this drug.
Patients taking LIRAGLUTIDE who experience pancreatitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PANCREATITIS is a less commonly reported adverse event for LIRAGLUTIDE, but still significant enough to appear in the safety profile.
In addition to pancreatitis, the following adverse reactions have been reported for LIRAGLUTIDE:
The following drugs have also been linked to pancreatitis in FDA adverse event reports:
PANCREATITIS has been reported as an adverse event in 2,318 FDA reports for LIRAGLUTIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PANCREATITIS accounts for approximately 2.9% of all adverse event reports for LIRAGLUTIDE, making it a notable side effect.
If you experience pancreatitis while taking LIRAGLUTIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.